MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
COLL Collegium Pharmaceutical
- 29.700
- -0.740-2.43%
Close Dec 20 16:00 ET
- 30.000
- +0.300+1.01%
Post 20:01 ET
957.83MMarket Cap12.69P/E (TTM)
31.060High29.530Low1.38MVolume30.390Open30.440Pre Close41.23MTurnover4.56%Turnover Ratio23.02P/E (Static)32.25MShares42.28752wk High4.09P/B897.06MFloat Cap28.97052wk Low--Dividend TTM30.20MShs Float42.287Historical High--Div YieldTTM5.03%Amplitude7.370Historical Low29.905Avg Price1Lot Size
About Collegium Pharmaceutical Company
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
Company Profile
SymbolCOLL
Company NameCollegium Pharmaceutical
Listing DateMay 7, 2015
Issue Price12.00
Founded2002
CEOMr. Vikram Karnani
MarketNASDAQ
Employees197
Fiscal Year Ends12-31
Address100 Technology Center Drive,Suite 300
CityStoughton
ProvinceMassachusetts
CountryUnited States of America
Zip Code02072
Phone1-781-713-3699
Company Executives
- Name
- Position
- Salary
- Vikram Karnani
- Director, President and Chief Executive Officer
- --
- Shirley R. Kuhlmann
- Executive Vice President, General Counsel, Secretary and Chief Administrative Officer
- 2.87M
- Colleen Tupper
- Executive Vice President, Chief Financial Officer and Principal Accounting Officer
- 2.73M
- Scott Dreyer
- Executive Vice President and Chief Commercial Officer
- 2.61M
- Dr. Thomas B. Smith, M.D.
- Executive Vice President and Chief Medical Officer
- 2.04M
- Michael T. Heffernan, R.Ph.
- Chairman of the Board
- 330.61K
- Dr. Rita Balice-Gordon, PhD
- Independent Director
- 275.61K
- Dr. John G. Freund,M.D.
- Independent Director
- 298.61K
- Gwen A. Melincoff
- Independent Director
- 275.61K
- Gino Santini
- Lead Independent Director
- 322.61K
- Garen G. Bohlin
- Independent Director
- 299.61K
- Dr. John A. Fallon, M.D.
- Independent Director
- 289.61K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.